TY - JOUR T1 - Hepatic Artery Injection of <sup>131</sup>I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 556 LP - 559 DO - 10.2967/jnumed.121.262136 VL - 63 IS - 4 AU - Hui Chen AU - Gang Nan AU - Ding Wei AU - Ren-You Zhai AU - Ming Huang AU - Wu-Wei Yang AU - Bao-Cai Xing AU - Xu Zhu AU - Hai-Feng Xu AU - Xiao-Dong Wang AU - Xiao-Yong Zhang AU - Bao-Rang Zhu AU - Peng Liu AU - Guang Cao AU - Song Gao AU - Chun-Yi Hao AU - Ren-Jie Yang AU - Jian-Hai Guo AU - Xin Zhang AU - Kun Gao AU - Kun Wang AU - Jian-Feng Wang AU - Zi-Yu Li AU - Lin-Zhong Zhu AU - Rong Ding AU - Jing Li AU - Ling Zhao AU - Yu-Jun Shao AU - Hai-Chun Liu AU - Jie-Lai Xia AU - Ling Wang AU - Ling-Min Kong AU - Zhi-Nan Chen AU - Huijie Bian Y1 - 2022/04/01 UR - http://jnm.snmjournals.org/content/63/4/556.abstract N2 - This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with 131I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. Results: The median time to tumor recurrence was 6 mo in the TACE + 131I-metuximab group (n = 160) and 3 mo in the TACE group (n = 160) (hazard ratio, 0.55; 95% CI, 0.43–0.70; P &lt; 0.001). The median overall survival was 28 mo in the TACE + 131I-metuximab group and 19 mo in the TACE group (hazard ratio, 0.62; 95% CI, 0.47–0.82; P = 0.001). Conclusion: TACE + 131I-metuximab showed a greater antirecurrence benefit, significantly improved the 5-y survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients. ER -